Arovella Therapeutics Ltd (ASX: ALA) Share Price and News

Price

$0.075

Movement

0.008 (-9.64%)

As at 13 Jun - Closed (20 mins delayed)

52 Week Range

$0.068 - $0.21

 
1 Year Return

-44.44%

Arovella Therapeutics Ltd Chart and Price Data

2025
2025
2025
2025
$0.00
$0.10
$0.20
$0.00
$0.10
$0.20
$0.00
$0.10
$0.20
$0.00
$0.10
$0.20

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $88.79 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.18 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -52.94%
Earnings Yield N/A
Franking -
Earnings Yield

N/A

Franking

-

Dividend per share

N/A

Year To Date Return

-52.94%

Shares Outstanding

1.18 billion

Earnings per share

-0.006

Share Price

$0.075

Day Change

0.008 (-9.64%)

52 Week Range

$0.068 - $0.21

Yesterday's Close

$0.083

Today's Open

$0.082

Days Range

$0.074 - $0.084

Volume

4,804,237

Avg. Volume (1 month)

1,814,974

Turnover

$371,290

As at 13 Jun - Closed

  • Arovella Therapeutics Ltd (ASX: ALA)
    Latest News

    Share Market News

    Suda Pharmaceuticals share price soars 200% on TGA approval

    The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.

    Read more »

    ALA ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    8th May 2025 2025-05-08T14:12:51 Results of Extraordinary General MeetingYesNo2:12pm2222k
    5th May 2025 2025-05-05T11:06:06 ALA exclusive iNKT technology option with BaylorYesNo11:06am3260k
    29th Apr 2025 2025-04-29T11:03:12 Investor webinar presentationYesNo11:03am363.8M
    24th Apr 2025 2025-04-24T14:24:54 Notification regarding unquoted securities - ALAYesNo2:24pm617k
    16th Apr 2025 2025-04-16T08:21:57 Quarterly Update WebinarYesNo8:21am2187k
    16th Apr 2025 2025-04-16T08:21:47 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo8:21am12809k
    10th Apr 2025 2025-04-10T10:29:24 Notice of Extraordinary General Meeting/Proxy FormYesNo10:29am17918k
    1st Apr 2025 2025-04-01T10:32:10 Cancel - Proposed issue of securities - ALAYesNo10:32am515k
    1st Apr 2025 2025-04-01T10:27:55 Cancel - Proposed issue of securities - ALAYesNo10:27am515k
    27th Mar 2025 2025-03-27T09:10:36 Notification of cessation of securities - ALAYesNo9:10am413k

    About Arovella Therapeutics Ltd

    Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. Its activities include pharmaceutical development of drug delivery technology and medical devices and consumables distribution. The company operates through following business segment: Suda; and Malaria Research Company. The Suda segment includes research and development to create new human pharmaceutical products by combining proven drugs with innovated, patented, delivery technologies. The Malaria Research Company segment segment is the pharmaceutical development segment for the treatment of malaria. Arovella Therapeutics was founded on December 21, 1999 and is headquartered in Osborne Park, Australia.

    ALA Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jun 2025 $0.08 $-0.01 -12.05% 4,804,237 $0.08 $0.08 $0.07
    12 Jun 2025 $0.08 $0.00 0.00% 1,897,905 $0.08 $0.09 $0.08
    11 Jun 2025 $0.08 $0.00 0.00% 3,889,096 $0.08 $0.08 $0.08
    10 Jun 2025 $0.08 $0.00 0.00% 3,695,373 $0.08 $0.08 $0.07
    06 Jun 2025 $0.08 $0.00 0.00% 2,819,806 $0.08 $0.08 $0.07
    05 Jun 2025 $0.08 $0.00 0.00% 668,883 $0.08 $0.08 $0.08
    04 Jun 2025 $0.08 $0.00 0.00% 3,325,449 $0.08 $0.08 $0.08
    03 Jun 2025 $0.08 $0.00 0.00% 1,680,333 $0.08 $0.08 $0.08
    02 Jun 2025 $0.08 $0.00 0.00% 1,381,283 $0.08 $0.08 $0.07
    30 May 2025 $0.08 $0.00 0.00% 1,454,315 $0.08 $0.08 $0.08
    29 May 2025 $0.08 $0.00 0.00% 2,795,099 $0.08 $0.08 $0.07
    28 May 2025 $0.08 $0.00 0.00% 2,068,831 $0.07 $0.08 $0.07
    27 May 2025 $0.07 $0.00 0.00% 2,839,011 $0.08 $0.08 $0.07
    26 May 2025 $0.07 $0.00 0.00% 965,932 $0.08 $0.08 $0.07
    23 May 2025 $0.08 $0.00 0.00% 1,223,601 $0.07 $0.08 $0.07
    22 May 2025 $0.07 $-0.01 -12.99% 951,780 $0.08 $0.08 $0.07
    21 May 2025 $0.08 $0.00 0.00% 360,774 $0.08 $0.08 $0.08
    20 May 2025 $0.08 $0.00 0.00% 616,267 $0.08 $0.08 $0.08
    19 May 2025 $0.08 $0.00 0.00% 420,656 $0.08 $0.08 $0.08
    16 May 2025 $0.08 $0.00 0.00% 1,215,964 $0.08 $0.08 $0.08

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Nov 2024 Gary Phillips Issued 354,000 $65,490
    Director remuneration.
    26 Nov 2024 Thomas (Tom) Duthy Issued 620,000 $114,700
    Director remuneration.
    26 Nov 2024 Michael Baker Issued 1,658,483 $306,819
    Director remuneration.
    26 Nov 2024 Debora Barton Issued 354,000 $65,490
    Director remuneration. As per announcement on 29-11-2024
    26 Nov 2024 Elizabeth Stoner Issued 354,000 $65,490
    Director remuneration.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Gary Phillips Non-Executive Director Jul 2022
    Mr Phillips has more than 40 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.
    Dr Thomas (Tom) Duthy Non-Executive ChairmanNon-Executive Director Mar 2023
    Dr Duthy has over 20 years of direct financial markets experience and is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in the life sciences and technology sectors.
    Dr Michael Baker Chief Executive OfficerManaging Director Jan 2020
    Dr Baker has over 15 years of experience in scientific research, drug development and venture investing. He was an Investment Manager with leading Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities, and research institutes.
    Dr Debora Barton Non-Executive Director Aug 2021
    Dr Barton has over 20 years of oncology experience, which includes 9 years of clinical management of oncology patients and enrolling patients in clinical trials in academia. In the pharmaceutical industry, she has experience in medical affairs and clinical development in both large pharmaceutical and small biotech companies, including regulatory interactions in the USA, Europe, Australia, and several countries around the world.
    Dr Elizabeth Stoner Non-Executive Director Nov 2021
    Dr Stoner has over 30 years of experience in the life-science sector. She is currently an executive partner at MPM Capital, a leading US healthcare investment firm. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including Antiva, and Rhythm Pharmaceuticals.
    Mr Tim Luscombe Chief Financial OfficerCompany Secretary Dec 2023
    -
    Tim Luscombe Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    The Trust Company (Australia) Limited Mbf A/C 59,019,000 5.62%
    MB Investment Capital Pty Ltd 27,749,415 2.64%
    UBS Nominees Pty Ltd 25,620,196 2.44%
    Mr James Evan Hughes-Morris 21,917,196 2.09%
    Blackburne Capital Pty Ltd Blackburne Capital A/C 20,695,706 1.97%
    Mann Beef Pty Ltd 20,000,000 1.90%
    Mann Beef Pty Ltd i 19,555,555 1.86%
    DP Investment Capital Pty Ltd 18,000,000 1.71%
    Dylide Pty Ltd 17,166,666 1.63%
    TK Cooper Holdings Pty Ltd 15,186,620 1.45%
    M & M Stock One Pty Ltd The M & M Stock One A/C 13,596,581 1.29%
    Mr Neil Donald Delroy The Ndd Investment A/C 13,067,222 1.24%
    Ajava Holdings Pty Ltd 12,543,194 1.19%
    Murray James Way Pty Ltd 12,022,400 1.14%
    Mann Beef Pty Ltd Lochwall Super Fund A/C 11,350,102 1.08%
    Mrs Naomi Hughes Morris 11,309,868 1.08%
    Moovnup Pty Ltd Moovnup A/C 11,067,962 1.05%
    Widerange Corporation Pty Ltd 10,390,789 0.99%
    Mr Richard John Mann 10,000,000 0.95%
    Mr Brendan John Martin & Mrs Sharon Ann Martin Jaknic Super A/C 9,564,970 0.91%

    Profile

    since

    Note